Ben Synth examines why most Ozempic users quit within a year, uncovering the gap between clinical trial doses and real-world prescriptions. He explores cost barriers, dosing problems, side effects, and supply shortages that create apparent non-responders who were actually under-treated—revealing how healthcare system failures, not just biology, drive disappointment with GLP-1 medications.
Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV
This content was created in partnership and with the help of Artificial Intelligence AI
続きを読む
一部表示